Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial

IMPORTANCE: Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high burden for patients and limited existing therapeutic options. OBJECTIVE: To evaluate the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin 17A and 17F in individ...

Descripción completa

Detalles Bibliográficos
Autores principales: Glatt, Sophie, Jemec, Gregor B. E., Forman, Seth, Sayed, Christopher, Schmieder, George, Weisman, Jamie, Rolleri, Robert, Seegobin, Seth, Baeten, Dominique, Ionescu, Lucian, Zouboulis, Christos C., Shaw, Stevan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374742/
https://www.ncbi.nlm.nih.gov/pubmed/34406364
http://dx.doi.org/10.1001/jamadermatol.2021.2905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374742/
https://www.ncbi.nlm.nih.gov/pubmed/34406364
http://dx.doi.org/10.1001/jamadermatol.2021.2905

Ejemplares similares